Advanced Search

Neurocrine Biosciences Stocks List

Symbol Grade Name % Change
NBIX F Neurocrine Biosciences, Inc. -6.32
SPRB F Spruce Biosciences, Inc. 0.05
View As Page of Charts
Related Industries: Biotechnology
Related Stock Lists: Adrenal Gland Disorders Alcohols Anatomy Biopharmaceutical Boehringer Ingelheim Cardiovascular Disease Cardiovascular Diseases Classic Congenital Adrenal Hyperplasia Clinical Development Congenital Adrenal Hyperplasia Diabetes Disorders Dyskinesia Endocrine Disorders Endometriosis Epilepsy Essential Tremor Ethers Fibroids Gnrh Antagonists

Related ETFs - A few ETFs which own one or more of the above listed Neurocrine Biosciences stocks.

Symbol Grade Name Weight
FBT F First Trust Amex Biotech Index Fund 3.46
BBP D BioShares Biotechnology Products Fund 2.33
BBH D Market Vectors Biotech ETF 2.16
LABD F Direxion Daily S&P Biotech Bear 3X Shares 1.62
BIS D ProShares UltraShort Nasdaq Biotechnology 1.16
View all Neurocrine Biosciences related ETFs...
Compare ETFs
  • Compare BBH to BIS
  • Compare FBT to BIS
  • Compare LABD to BIS

    • Recent Signals

    Date Stock Signal Type
    2021-03-03 NBIX Lower Bollinger Band Walk Weakness
    2021-03-03 SPRB NR7 Range Contraction
    2021-03-03 SPRB Narrow Range Bar Range Contraction
    2021-03-03 SPRB Stochastic Reached Oversold Weakness
    2021-03-03 SPRB MACD Bearish Signal Line Cross Bearish

    Recent News for Neurocrine Biosciences Stocks

    Date Stock Title
    Mar 2 NBIX Neurocrine Biosciences' INTERACT Study Fails; Worse For Sentiment Than Value
    Mar 2 NBIX Neurocrine shares fall after mid-stage schizophrenia study results
    Mar 2 NBIX Neurocrine/Takeda's Luvadaxistat Fails To Improve Schizophrenia Symptom Severity
    Mar 2 SPRB Spruce Biosciences to Announce Phase 1 and 2 Data of Tildacerfont at Endocrine Society’s 2021 Annual Meeting
    Mar 2 NBIX Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS)
    Related Industries: Biotechnology
    Related Stock Lists: Adrenal Gland Disorders Alcohols Anatomy Biopharmaceutical Boehringer Ingelheim Cardiovascular Disease Cardiovascular Diseases Classic Congenital Adrenal Hyperplasia Clinical Development Congenital Adrenal Hyperplasia Diabetes Disorders Dyskinesia Endocrine Disorders Endometriosis Epilepsy Essential Tremor Ethers Fibroids Gnrh Antagonists

    Neurocrine Biosciences is a publicly traded biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.

    More about Neurocrine Biosciences
    Browse All Tags